Cian Healthcare Quarterly Results for Trading Insights
In 2026, Cian Healthcare (CHCL) reported revenue ₹0 Cr and net profit ₹0 Cr. Compare with Cian Healthcare value estimation to assess whether the stock is under or overvalued.
CHCL Quarterly Results — Revenue, Profit & EPS Highlights
Cian Healthcare latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit CHCL share price.
- Revenue of ₹31 Cr in March 2025 (+0.0% vs March 2025, -50.0% vs March 2024)
- Net Profit of ₹-26 Cr in March 2025 (+0.0% vs March 2025, -2700.0% vs March 2024)
- EBITDA of ₹-6 Cr in March 2025 (+0.0% vs March 2025)
- Operating Margin of -22.0% in March 2025 (+0.0pp vs March 2025)
- Earnings Per Share of ₹-10.39 in March 2025 (+0.0% vs March 2025)
Cian Healthcare Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CHCL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 0 | 31 | 62 | 69 | 78 | - | - |
| Net Profit (₹ Cr) | 0 | -26 | 1 | 2 | -6 | - | - |
| EBITDA (₹ Cr) | 0 | -6 | 11 | 13 | 5 | - | - |
| EPS (₹) | 0.00 | -10.39 | 0.34 | 0.81 | -2.21 | - | - |
| Operating Margin (%) | 0.0% | -22.0% | 18.0% | 18.0% | 5.0% | - | - |
CHCL Share Price Trend — 1-Year Movement Across Quarterly Results
Cian Healthcare 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore CHCL share price charts to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CHCL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Cian Healthcare latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹443,373.10 Cr | 1863.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 143.3 |
|
Divis Laboratories
Sept 2025 |
₹178,235.60 Cr | 6921.5 | 2,860 | 689 | +7.1% | - | 24.1% | 266.5 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹145,389.39 Cr | 4403.9 | 3,219 | 591 | +11.3% | - | 18.4% | 251.1 |
|
Cipla
Mar 2026 |
₹107,240.96 Cr | 1436.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹105,607.38 Cr | 1303.6 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 491.9 |
All amounts in ₹ Crores